Details

Autor(en) / Beteiligte

• Nishimura, Takashi
• Iijima, Hiroko
• Nishikawa, Hiroki
• Kondo, Reiichiro
• Yano, Hirohisa
• Kage, Masayoshi
• Aoki, Tomoko
• Nakano, Chikage
• Yuri, Yukihisa
• Ishii, Noriko
• Hasegawa, Kunihiro
• Takata, Ryo
• Yoh, Kazunori
• Sakai, Yoshiyuki
• Takashima, Tomoyuki
• Aizawa, Nobuhiro
• Ikeda, Naoto
• Iwata, Yoshinori
• Enomoto, Hirayuki
• Hirota, Seiichi
• Fujimoto, Jiro
• Nishiguchi, Shuhei

Titel

Liver fibrosis markers as assessed by ultrasound elastography and serum samples: A large comparative study in hepatitis virus B and C liver diseases

Ist Teil von

• Hepatology research, 2019-07, Vol.49 (7), p.721-730

Ort / Verlag

Netherlands: Wiley Subscription Services, Inc

Erscheinungsjahr

2019

Quelle

Wiley Online Library All Journals

Beschreibungen/Notizen

• Aim We aimed to compare the well‐established liver fibrosis (LF) markers in Japanese patients with chronic hepatitis B (CHB, n = 331) and chronic hepatitis C (CHC, n = 886) and to discuss possible causes of differences in results between CHB patients and CHC patients. Methods Virtual touch quantification (VTQ) in acoustic radiation force impulse, Fibrosis‐4 (Fib‐4) index, aspartate aminotransferase to platelet ratio index (APRI), and hyaluronic acid (HA) were compared between the two cohorts. As an additional investigation, total collagen proportional area (TCPA, %) was tested using liver pathological samples (n = 83). Results Significant LF (F2 or greater) and advanced LF (F3 or greater) were identified in 153 (46.2%) and 76 (23.0%) patients in the CHB cohort and 579 (65.3%) and 396 (44.7%) patients in the CHC cohort. The median VTQ, Fib‐4 index, APRI, and HA values in the CHB cohort were 1.20 m/s, 1.36, 0.44, and 25 ng/mL; those in the CHC cohort were 1.32 m/s, 2.60, 0.74, and 65.5 ng/mL (P‐values, all <0.0001). Similar tendencies were noted by F stage‐based stratification. The median TCPA in the CHB cohort and the CHC cohort were 8.5% and 12.7% (P < 0.0006). The TCPA values in the CHC cohort were higher than those in the CHB cohort regardless of LF stage. Conclusion Values of LF markers in CHB patients can differ from those in CHC patients even in the same LF stage. Difference in total amount of collagen fiber in CHB and CHC appears to be linked to the difference.